Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Candidiasis chronic mucocutaneous

Systemic fungal infections Candidiasis, chronic mucocutaneous candidiasis, oral... [Pg.1660]

Histoplasmosis, blastomycosis, systemic candidiasis, chronic mucocutaneous candidiasis, coccidioidomycosis, paracoccidioidomycosis, chromomycosis, seborrheic dermatitis,... [Pg.661]

It is indicated in dermatophytoses, tinea versicolor, onychomycoses, oropharyngeal candidiasis, cutaneous candidiasis, chronic mucocutaneous candidiasis, oculomycoses systemic mycoses like cryptococcosis, candidiasis and aspergillosis subcutaneous mycoses like sporotrichosis and chromomycosis. [Pg.346]

Indications Treatment of the following systemic fungal infections Candidiasis Chronic mucocutaneous candidiasis Oral thrush Candiduria Blastomycosis Coccidioidomycosis Histoplasmosis Chromomycosis Paracoccidioidomycosis... [Pg.64]

Lilic D New perspectives on the immunology of chronic mucocutaneous candidiasis. Curr Opin Infect Dis 2002 15 143-147. [Pg.135]

Lammas DA, Drysdale P. Calvert JE. Cant AJ, Abinun M Deregulated production of protective cytokines in response to Candida albicans infection in patients with chronic mucocutaneous candidiasis. Infect Immun 2003 71 5690-5699. [Pg.136]

Use only to treat severe systemic fungal disease Coccidioidomycosis, candidiasis, cryptococcosis, pseudoallescheriosis (petriellidiosis, allescheriosis), paracoccidioidomycosis, and for the treatment of chronic mucocutaneous candidiasis. [Pg.1658]

Younger than 2 years of age) - Daily dosage has not been established. Minimum treatment is 1 or 2 weeks for candidiasis and 6 months for the other indicated systemic mycoses. Chronic mucocutaneous candidiasis usually requires maintenance therapy. [Pg.1661]

Patients with chronic mucocutaneous candidiasis respond well to a once-daily dose of 200 mg of ketoconazole, with a median clearing time of 16 weeks. Most patients require long-term maintenance therapy. Variable results have been reported in treatment of chromomycosis. [Pg.1290]

Humans with deficient IFNy response show several immunological defects, such as increased susceptibility to infections with intracellular pathogens. Impaired IFNy production has been demonstrated in human pathological conditions, namely chronic mucocutaneous candidiasis and systemic lupus erythematosus. ... [Pg.701]

Lflic D, Cant AJ, Abinun M, et al. Chronic mucocutaneous candidiasis. I. Altered antigen-stimulated TL-2, IL-4, IL-6 and interferon-gamma (IFN-y) production. Chn Exp Immuno 1996 105 205-12,... [Pg.734]

Thymus transplantation has also been employed experimentally in a variety of conditions including chronic mucocutaneous candidiasis, ataxia-telangiectsia, and Wiscott-Aldrich syndrome, but in these cases results have generally been disappointing (reviewed in Pahwa et al., 1979 Skotnicki et al., 1984). Thus, the only immunodeficiency state that has clearly demonstrated a lasting improvement of T cell immunity following thymus transplantation is DiGeorge s syndrome. [Pg.255]

Of the thymic hormones currently undergoing clinical evaluation, the most detailed pharmacokinetic studies have been performed with TF5 and Tuj. The parenteral administration of TF5 has been associated with the generation of detectable serum thymic hormone bioactivity as detected in the Bach-Dardenne assay (Iwata et ah, 1981). A 10-year-old child with chronic mucocutaneous candidiasis treated with TF5 showed a prompt rise of serum FTS-like bioactivity that persisted within the normal range for several weeks following the discontinuation of treatment, but which eventually returned to low levels (Iwata et ah, 1981). These studies have clearly demonstrated that the parenteral administration of TF5 generates detectable serum bioactivity. However, it cannot be determined which of the peptides present in TF5 gave rise to the serum activity. [Pg.271]

DOC Paracoccidioides brasiliensis, thrush (pharyngeal Candida). Also for Tx of chronic mucocutaneous candidiasis, dermatophytes (including griseofulvin-resistant). [Pg.116]

Fischer TJ, Klein RB, Kershnar HE, Borut TC, Stiehm ER (1977) Miconazole in the treatment of chronic mucocutaneous candidiasis a preliminary report. J Pediatr 91 815-819... [Pg.576]


See other pages where Candidiasis chronic mucocutaneous is mentioned: [Pg.374]    [Pg.374]    [Pg.125]    [Pg.424]    [Pg.145]    [Pg.147]    [Pg.148]    [Pg.148]    [Pg.242]    [Pg.664]    [Pg.2163]    [Pg.267]    [Pg.368]    [Pg.605]    [Pg.606]    [Pg.421]    [Pg.70]    [Pg.117]    [Pg.119]    [Pg.1289]    [Pg.1445]   
See also in sourсe #XX -- [ Pg.148 ]




SEARCH



Candidiasis

Mucocutaneous candidiasis

© 2024 chempedia.info